Quick Answer
Petros Pharmaceuticals, Inc. reported Total Assets of $10.64 million for the year ending 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -68.5% in Total Assets from 2023 to 2024.
- This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $66.15 million | Q2 2021: $56.67 million | Q3 2021: $52.04 million | Q1 2022: $55.86 million | Q2 2022: $51.05 million | Q3 2022: $37.70 million | Q1 2023: $30.57 million | Q2 2023: $28.73 million | Q3 2023: $38.91 million | Q1 2024: $30.31 million | Q2 2024: $25.17 million | Q3 2024: $20.69 million | Q4 2024: $10.64 million | Q1 2025: $17.61 million | Q2 2025: $7.40 million | Q3 2025: $6.13 million.
- Over the full 5 years of available data (2020 to 2024), Petros Pharmaceuticals, Inc.'s Total Assets has declined by 84.8%.
- Historical annual values: Fiscal year 2024: $10.64 million | Fiscal year 2023: $33.80 million | Fiscal year 2022: $32.42 million | Fiscal year 2021: $67.39 million | Fiscal year 2020: $69.85 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: